Clinical results of active surveillance for extra‐abdominal desmoid‐type fibromatosis

Sakai, Takeharu; Nishida, Yoshihiro; Ito, Kan; Ikuta, Kazunari; Urakawa, Hiroshi; Koike, Hiroshi; Imagama, Shiro

doi:10.1002/cam4.5329

Cited by 3 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent prospective study has shown that S45F mutation is associated with tumor progression (HR = 6.24 [95% CI 1.92–20.30]) and suggests the onset of active treatment (AT) during the AS ( 44 ). Compared with tumor diameter, gender, recurrence cases and other clinical factors, S45F mutation is significantly related to 3-year RFS ( 45 ). It has been reported that CTNNB1 mutation types was associated with tumor progression and aggressive treatment with adjuvant radiotherapy was administered accordingly.…”

Section: Biomarkers In Asmentioning

confidence: 99%

Novel insights into biomarkers of progression in Desmoid tumor

et al. 2023

View full text Add to dashboard Cite

Desmoid tumor (DT) is a rare neoplasm characterized by the proliferation of myofibroblastic cells that infiltrates and invades adjacent tissues. Due to its locally aggressive and recurrent nature, DT often causes local symptoms and can be challenging to manage clinically. Therefore, identifying biomarkers that can predict the progression of DT and guide treatment decisions is critical. This review summarizes several biomarkers that have been implicated in active surveillance (AS) and the prediction of postoperative recurrence and attempts to elucidate their underlying mechanisms. Some of these novel markers could provide prognostic value for clinicians, and ultimately help facilitate optimal and accurate therapeutic decisions for DT.

show abstract

Section: Biomarkers In Asmentioning

confidence: 99%

Novel insights into biomarkers of progression in Desmoid tumor

et al. 2023

View full text Add to dashboard Cite

show abstract

Clinical results of active surveillance for extra‐abdominal desmoid‐type fibromatosis

et al. 2022

View full text Add to dashboard Cite

Desmoid-type fibromatosis (DF) is a (myo-) fibroblastic soft tissue tumor that is classified as an intermediate malignancy according to the World Health Organization classification. 1 DF is highly locally invasive and has a high postoperative recurrence rate. It does not cause distant metastasis like soft tissue sarcomas. Additionally, it may spontaneously regress or disappear without any treatment in some patients, thus it has been named an "enigmatic"

show abstract

A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes

Wilke

Garner

Bestic

et al. 2022

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: The purpose of this pilot study was to examine the clinical efficacy and safety of serial triamcinolone injections for the treatment of desmoid tumors. Experimental Design: Nine patients were enrolled into this prospective study and underwent three serial ultrasound-guided triamcinolone injections (120 mg) at six-week intervals. Magnetic resonance imaging was compared at baseline and every 6 months, out to 24 months. Safety and tolerability were assessed by clinical evaluation and questionnaires, including the 12-item short form survey (SF-12), visual analog scale (VAS), and desmoid patient-reported outcome (PRO) tool. Results: At 24 months, 8 (88.9%) patients demonstrated a reduction in the volume of their tumor while 1 (11.1%) enlarged. Median tumor volume change was -26.9% (-81.1% to 34.6%, P = 0.055) All 9 tumors remained stable based on WHO criteria, whereas 2 (22.2%) demonstrated partial response based on RECIST. There was a significant decrease in the tumor:muscle postcontrast mean signal intensity ratio at 6 months (P = 0.008) and 24 months (P = 0.004). There was a similar decrease in the tumor:muscle T2 mean signal intensity ratio at 24 months (P = 0.02). We found no difference in the SF-12 and VAS scores, but there were significant improvements in the desmoid PRO. Conclusions: Treatment of desmoid tumors with serial triamcinolone injections appears safe and well-tolerated by patients, with a 22% partial response based on RECIST. Further research is needed to confirm our results and determine factors predictive of response.

show abstract

Clinical results of active surveillance for extra‐abdominal desmoid‐type fibromatosis

Cited by 3 publications

References 48 publications

Novel insights into biomarkers of progression in Desmoid tumor

Novel insights into biomarkers of progression in Desmoid tumor

Clinical results of active surveillance for extra‐abdominal desmoid‐type fibromatosis

A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes

Contact Info

Product

Resources

About